News EyePoint Pharmaceuticals Reports Positive Masked Safety Update for Lead Product Candidate EYP-1901 in Ongoing PAVIA and DAVIO 2 Phase 2 Clinical Trials as of September 1, 2023 Staff September 11, 2023 Iframe sync Post navigation Previous: Madrigal Pharmaceuticals Appoints Bill Sibold as Chief Executive OfficerNext: Veru Reports Clinical Data from the Discontinued ARTEST Study of Enobosarm, Novel Selective Androgen Receptor Targeting Agonist, in AR+ ER+ HER2- Metastatic Breast Cancer More Stories Diagnostics EHR Healthcare News Pharmaceutical Pre-JPM Investor Pulse Signals 2026 Capital Rotation Toward “AI That Ships,” Admin Cost Takeout, and Differentiated Metabolic Assets With Special-Situations Capital Back in Scope Staff January 11, 2026 Clinical Trial DNA News Benitec Biopharma Provides Positive Long-Term Clinical Study Results for BB-301 Phase 1b/2a Clinical Trial Demonstrating Robust Efficacy and Continued Durability of Response Staff January 11, 2026 Cancer Clinical Trial Healthcare News Pharmaceutical Pregnancy Best GLP-1 Weight Loss Shot (2026): Direct Meds Reviews Prescription Access Pathways as New GLP-1 Formats Expand Staff January 11, 2026
